PHASE II STUDY OF CONCOMITANT THALIDOMIDE DURING RADIOTHERAPY FOR HEPATOCELLULAR CARCINOMA

Purpose: Thalidomide has been demonstrated to possess antitumor activity in patients with advanced hepatocellular carcinoma (HCC). The objective of the present study was to determine whether the combined treatment of thalidomide with radiotherapy (RI) is associated with acceptable toxicity and an improved clinical outcome in FICC patients. Methods and Materials: A total of 24 patients were enrolled to receive RT combined with thalidomide. A total dose of 50 Gy was delivered in 2-Gy fractions within 5 weeks. Thalidomide was administered 1100 mg twice daily starting 3 days before RT until the development of unacceptable toxicity or disease progression. Blood samples were collected before, during, and after treatment to measure the levels of angiogenic factors and cytokines. The results of patients receiving the combined therapy were compared with those from 18 HCC patients receiving RT only. Results: No significant difference in the clinical parameters was noted between the two groups, except for the baseline interleukin-6 level, which was greater in the concomitant group (p = .05). The most common toxicities related to thalidomide use were skin rash (54.2%), somnolence (37.5%), and constipation (33.3%). No significant differences were seen in the response rate (55.6% vs. 58.3%,p = .48), median progression-free survival (182 +/- 48.9 vs. 148 +/- 6.2 days, p = .15), or median overall survival (258 +/- 45.6 vs. 241 +/- 38.6, p = .16) between those who received. concomitant therapy and those who received RT alone. Thalidomide suppressed the serum basic fibroblast growth. factor level significantly during RT (p = .03) and, to a lesser extent, the interleukin-6 and tumor necrosis factor-alpha levels. After adjusting for other potential prognostic factors in the multivariate analysis, only the baseline interleukin-6 level and stem cell-derived factor-1 during RT independently predicted the progression-free survival.. A decreased serum stem cell-derived factor-1. level 1 month after RI completion was a significant predictor of the overall survival of HCC patients receiving RT. Conclusions: Despite the acceptable toxicity, thalidomide provided no additional benefit for HCC patients undergoing RT. (C) 2012 Elsevier Inc.